NEW YORK (GenomeWeb) – OncoCyte said today that its second quarter net loss rose, compared to the same period last year, as it prepares to launch a noninvasive lung cancer diagnostic dubbed DetermaVu.

The liquid biopsy firm's net loss for the three months ended June 30, 2017 was $3.8 million, or $.13 per share, compared to a loss of $2.5 million, or $.10 per share in Q2 2016. The consensus Wall Street estimate was for a loss of $.12 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.